ACADIA Pharmaceuticals Inc (ACAD): Forward P/E Multiple
ACADIA Pharmaceuticals combines a niche-capture strategy with the management of patent disputes regarding Nuplazid. The company's forward P/E reflects valuation dynamics, with the current metric standing at 17.50. Its monopoly pricing power over orphan drugs provides the business with stability until the expiration of its exclusive rights.
Analytical breakdowns for ACADIA Pharmaceuticals
- stock quotes and analyst forecast:
- stock exchange capitalization data:
- book capitalization information:
- company liabilities and liquidity data:
Total Debt to Capital ACADIA Pharmaceuticals|ACAD - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio ACADIA Pharmaceuticals|ACAD - Aggregate Debt Obligations|Debt to Book Capitalization Ratio ACADIA Pharma|ACAD - Long-Term Liabilities|Company Short-Term Debts ACADIA Pharmaceuticals|Quick Ratio acadia-pharm.com
- earnings and market ratios statistics:
ACAD - Net Profit|Expected Profit ACADIA Pharmaceuticals|ACAD - Company Value to Net Income|Future Price to Earnings ACADIA Pharmaceuticals Inc|ACAD - Price/Earnings to Growth Multiple|EV/EBITDA Multiple ACADIA Pharma|ACAD - Operating profit EBITDA|Net earnings per share (EPS TTM) ACADIA Pharmaceuticals|ACAD - Net earnings per share for the last 12 months|Quarterly EPS earnings growth acadia-pharm.com|ACAD - Earnings per share growth rate in current year|Expected earnings per share growth for next year ACADIA Pharmaceuticals
Fundamental valuation:ACAD ACADIA Pharmaceuticals Inc.
Forward P/E is calculated as the ratio of a stock's current market value to its projected earnings per share, measuring the market's willingness to pay a premium for future cash flows. For ACADIA Pharmaceuticals (ACAD), the trajectory of the company's future price-to-earnings multiple reflects expectations for the scalability of its CNS biotech solutions, where low production costs combined with global patent coverage should drive rapid net income growth.
Competitor analysis for ACADIA Pharmaceuticals
Forward P/E Multiple BIIB|Projected Price to Earnings Neurocrine NBIX|Forward P/E Multiple RGC (Regencell)|Forward P/E Multiple Axsome Corp AXSM|Xenon Pharmaceuticals - Forward P/E Multiple|VKTX (vikingtherapeutics.com) - Price to Future Earnings Ratio|SUPN: Forward P/E Multiple|CPRX - Market Cap to Projected Earnings|DNLI (Denali Therapeutics Inc) - Forward P/E Multiple|Forward P/E Multiple Harmony Corp|Projected Price to Earnings BHVN (Biohaven Ltd.)|AMLX (amylyx.com) - Future Price to Earnings Multiple|Future Price to Earnings Trevi Therapeutics, Inc. TRVI|PRAX (Praxis Precision Medicines Inc) - Price to Expected Earnings Ratio|Anavex Corp - Forward P/E Multiple|Future Price to Earnings Multiple CBLL (CeriBell EEG)|PRTA: Forward P/E Multiple|Alector (ALEC) - Forward P/E Multiple|Future Price to Earnings Annexon|OMER: Future Price to Earnings Multiple|Future Price to Earnings Neurogene Corp (NGNE)|Projected Price to Earnings AC Immune Inc ACIU|Forward P/E Multiple VYGR (Voyager Therapeutics)|Forward P/E Multiple neumoratx.com NMRA|Scilex - Forward P/E Multiple|Tevogen Bio Holdings Inc. (TVGN) - Projected Price to Earnings|ACOG: Forward P/E Multiple|Projected Price to Earnings Ratio Cognition Therapeutics Inc. (CGTX)|Projected Price to Earnings IKT|Forward P/E Multiple cassavasciences.com|Projected Price to Earnings ASRT (Assertio Holdings, Inc.)|Market Cap to Future Earnings Ratio COYA|Forward P/E Multiple VTGN (Vistagen)|Market Cap to Projected Earnings Ovid Therapeutics Inc (OVID)|Acumen Pharmaceuticals - Forward P/E Multiple|cervomed.com (CRVO) - Projected Price to Earnings|ATHE: Forward P/E Multiple|Clene (CLNN) - Forward P/E Multiple|Future Price to Earnings PepGen Inc|Future Price to Earnings JUNS|Future Price to Earnings Relmada Therapeutics (RLMD)|Market Cap to Projected Earnings annovisbio.com|Forward P/E Multiple GRCE (Grace Therapeutics)|Forward P/E Multiple Firefly Neuroscience, Inc. AIFF|ANEW Medical, Inc. - Forward P/E Multiple|NeuroSense Therapeutics (NRSN) - Projected Price to Earnings|RVPH: Forward P/E Multiple|MetaVia (MTVA) - Forward P/E Multiple|NRXS (NeurAxis) - Forward P/E Multiple|Price to Future Earnings Ratio HSDT (Helius Medical Technologies Inc.)|Future Price to Earnings Passage Bio, Inc. (PASG)|bionomics.com.au - Price to Future Earnings Ratio|Forward P/E Multiple NERV (Minerva Neurosciences)|athira.com (ATHA) - Projected Price to Earnings Ratio|ADXN: Projected Price to Earnings|ALZN - Forward P/E Multiple|cyclerion.com (CYCN) - Future Price to Earnings|Protagenic Therapeutics, Inc. - Future Price to Earnings Multiple|Future Price to Earnings Pasithea Therapeutics Corp|Projected Price to Earnings Ratio Cortigent Medical CRGT|Forward P/E Multiple ATXI|Forward P/E Multiple Brainstorm Cell Therapeutics Inc. (BCLI)|Forward P/E Multiple CARA (Cara Therapeutics, Inc)|CHRO - Projected Price to Earnings|Eliem - Forward P/E Multiple|ITCI - Forward P/E Multiple|LBPH: Forward P/E Multiple|Price to Future Earnings Ratio MRNS|NKGN (NKGen) - Forward P/E Multiple|NeuroBo Pharma (NRBO) - Market Cap to Projected Earnings|Forward P/E Multiple SAGE|Forward P/E Multiple synaptogen.com (SNPX)|Trevena - Projected Price to Earnings|Future Price to Earnings Multiple VIGL|WENA - Future Price to Earnings|Price to Expected Earnings Ratio CERE
